These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38191194)

  • 1. Enhanced immunity against SARS-CoV-2 in returning Chinese individuals.
    Yuan R; Chen H; Yi L; Li X; Hu X; Li X; Zhang H; Zhou P; Liang C; Lin H; Zeng L; Zhuang X; Ruan Q; Chen Y; Deng Y; Liu Z; Lu J; Xiao J; Chen L; Xiao X; Li J; Li B; Li Y; He J; Sun J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2300208. PubMed ID: 38191194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute respiratory syndrome coronavirus 2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination.
    Wang X; Li Y; Jin J; Chai X; Ma Z; Duan J; Zhang G; Huang T; Zhang X; Zhang T; Wu H; Cao Y; Su B
    Chin Med J (Engl); 2024 Nov; 137(22):2734-2744. PubMed ID: 39028115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
    Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J
    Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R;
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from
    Niu M; Mu Y; Adriko M; Candia R; Jones MK; McManus DP; Egwang TG; Cai P
    Front Public Health; 2024; 12():1437063. PubMed ID: 39624416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
    JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China.
    Li J; Xu J; Liu Y; Chen L; Yu L; Xiao X; Wang Q
    Hum Vaccin Immunother; 2024 Dec; 20(1):2389602. PubMed ID: 39171541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis.
    Martin CA; Nazareth J; Jarkhi A; Pan D; Das M; Logan N; Scott S; Bryant L; Abeywickrama N; Adeoye O; Ahmed A; Asif A; Bandi S; George N; Gohar M; Gray LJ; Kaszuba R; Mangwani J; Martin M; Moorthy A; Renals V; Teece L; Vail D; Khunti K; Moss P; Tattersall A; Hallis B; Otter AD; Rowe C; Willett BJ; Haldar P; Cooper A; Pareek M
    EClinicalMedicine; 2023 Apr; 58():101926. PubMed ID: 37034357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    Jia T; Wang F; Chen Y; Liao G; Xu Q; Chen J; Wu J; Li N; Wang L; Yuan L; Wang D; Xie Q; Luo C; Luo H; Wang Y; Chen Y; Shu Y
    J Infect; 2024 Dec; 89(6):106362. PubMed ID: 39608577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.
    Pearce FA; Lim SH; Bythell M; Lanyon P; Hogg R; Taylor A; Powter G; Cooke GS; Ward H; Chilcot J; Thomas H; Mumford L; McAdoo SP; Pettigrew GJ; Lightstone L; Willicombe M
    Lancet Rheumatol; 2023 Aug; 5(8):e461-e473. PubMed ID: 38251578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
    Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H
    Front Immunol; 2024; 15():1448408. PubMed ID: 39606247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.
    Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A
    Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
    Cerqueira-Silva T; Shah SA; Robertson C; Sanchez M; Katikireddi SV; de Araujo Oliveira V; Paixão ES; Rudan I; Junior JB; Penna GO; Pearce N; Werneck GL; Barreto ML; Boaventura VS; Sheikh A; Barral-Netto M
    PLoS Med; 2023 Jan; 20(1):e1004156. PubMed ID: 36630477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi.
    Mseka UL; Mandolo J; Nyoni K; Divala O; Kambalame D; Mapemba D; Kamzati M; Chibwe I; Henrion MYR; Manda K; Thindwa D; Mvula M; Odala B; Kamng'ona R; Dzinza N; Jere KC; Feasey N; Ho A; Amoah AS; Gordon M; Swarthout TD; Crampin A; Heyderman RS; Kagoli M; Chitsa-Banda E; Mitambo C; Phuka J; Chilima B; Kasambara W; Jambo KC; Chauma-Mwale A
    EClinicalMedicine; 2023 Feb; 56():101800. PubMed ID: 36600885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of SARS-CoV-2 in Healthcare Workers Before and After COVID-19 Vaccination: A Cohort Study in a Primary Care Unit of Brazil.
    Torres ACP; de Brito RN; de Araújo WN; Pedrette P; Alves DCC; Teixeira AIP; Gontijo CC; Romero GAS; Gurgel-Gonçalves R; Ramalho WM
    Healthcare (Basel); 2024 Nov; 12(22):. PubMed ID: 39595495
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.